

RESEARCH ARTICLE

Menopausal hormone therapy and women's health: An umbrella review

Guo-Qiang Zhang^{1*}, Jin-Liang Chen², Ying Luo³, Maya B. Mathur⁴, Panagiotis Anagnostis⁵, Ulugbek Nurmatov⁶, Madar Talibov⁷, Jing Zhang⁸, Catherine M. Hawrylowicz⁹, Mary Ann Lumsden¹⁰, Hilary Critchley¹¹, Aziz Sheikh¹², Bo Lundbäck¹, Cecilia Lässer¹, Hannu Kankaanranta^{1,13,14}, Siew Hwa Lee¹⁵, Bright I. Nwaru^{1,12,16}

1 Krefling Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, **2** Department of Geriatrics, First Affiliated Hospital of Chongqing Medical University, Chongqing, China, **3** Department of Gastroenterology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China, **4** Quantitative Sciences Unit, Stanford University, Palo Alto, California, United States of America, **5** Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, **6** Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, United Kingdom, **7** UMR1086 INSERM—Unité de Recherche Interdisciplinaire pour la Prévention et le Traitement des Cancers (ANTICIPE), Centre de Lutte Contre le Cancer François Baclesse, Caen, France, **8** Department of Intensive Care Unit, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China, **9** MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, London, United Kingdom, **10** Section of Reproductive and Maternal Medicine, Glasgow Royal Infirmary, School of Medicine, University of Glasgow, Glasgow, United Kingdom, **11** MRC Centre for Reproductive Health, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom, **12** Asthma UK Centre for Applied Research, Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom, **13** Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland, **14** Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland, **15** School of Nursing, Midwifery and Paramedic Practice, Robert Gordon University, Aberdeen, United Kingdom, **16** Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden

* These authors contributed equally to this work.

* guo-qiang.zhang@gu.se



OPEN ACCESS

Citation: Zhang G-Q, Chen J-L, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, et al. (2021) Menopausal hormone therapy and women's health: An umbrella review. *PLoS Med* 18(8): e1003731. <https://doi.org/10.1371/journal.pmed.1003731>

Academic Editor: Jenny E. Myers, University of Manchester, UNITED KINGDOM

Received: February 14, 2021

Accepted: July 12, 2021

Published: August 2, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pmed.1003731>

Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The statistical analysis protocol and R scripts are respectively available in [S3 Text](#) and [S4](#) and [S5 Texts](#). The datasets are publicly available at the Open Science

Abstract

Background

There remains uncertainty about the impact of menopausal hormone therapy (MHT) on women's health. A systematic, comprehensive assessment of the effects on multiple outcomes is lacking. We conducted an umbrella review to comprehensively summarize evidence on the benefits and harms of MHT across diverse health outcomes.

Methods and findings

We searched MEDLINE, EMBASE, and 10 other databases from inception to November 26, 2017, updated on December 17, 2020, to identify systematic reviews or meta-analyses of randomized controlled trials (RCTs) and observational studies investigating effects of MHT, including estrogen-alone therapy (ET) and estrogen plus progestin therapy (EPT), in perimenopausal or postmenopausal women in all countries and settings. All health

Framework (<https://osf.io/dsy37/>; DOI: [10.17605/OSF.IO/DSY37](https://doi.org/10.17605/OSF.IO/DSY37)).

Funding: GQZ was supported by the VBG Group Herman Krefting Foundation on Asthma and Allergy, and Sahlgrenska Academy, University of Gothenburg, Sweden. MBM was supported in part by the Franklin E. Fetzer Memorial Trust (award R2020-16). BIN was supported by the VBG Group Herman Krefting Foundation on Asthma and Allergy, Knut and Alice Wallenberg Foundation, and the Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Sweden. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: HC reports no conflicts specifically related to menopausal hormone therapy, and in the more general area of women's health the following are declared: Grant/Research Support in AUB treatment: Bayer AG; TAP Pharmaceuticals, Preglem/Gedeon-Richter; PEARL IV (with no personal remuneration); Speaker bureau on AUB Treatment: Bayer AG, Preglem/Gedeon-Richter, Myovant (with no personal remuneration); Consultancy/Advisory Board on AUB Treatment: Bayer AG, Preglem/Gedeon-Richter, Vifor Pharma, Myovant (with no personal remuneration); Royalties from UpToDate: for an article on abnormal uterine bleeding (personal remuneration received). AS is an Academic Editor on PLOS Medicine's editorial board. CL has co-developed extracellular vesicle-associated patents for putative clinical utilization and owns equity in Exocure Bioscience Inc. HK reports personal fees and non-financial support from AstraZeneca, personal fees from Chiesi Pharma AB, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Novartis, personal fees from Mundipharma, personal fees and non-financial support from Orion Pharma, personal fees from SanofiGenzyme, personal fees from GlaxoSmithKline, outside the submitted work. All other authors have declared that no competing interests exist.

Abbreviations: CHD, coronary heart disease; CI, confidence interval; EPT, estrogen plus progestin therapy; ET, estrogen-alone therapy; LDL-C, low-density lipoprotein cholesterol; MHT, menopausal hormone therapy; PI, prediction interval; PI(E)COS, Population, Intervention or Exposure, Comparator, Outcome, Study design; RCT, randomized controlled trial; RR, risk ratio; WHI, Women's Health Initiative.

outcomes in previous systematic reviews were included, including menopausal symptoms, surrogate endpoints, biomarkers, various morbidity outcomes, and mortality. Two investigators independently extracted data and assessed methodological quality of systematic reviews using the updated 16-item AMSTAR 2 instrument. Random-effects robust variance estimation was used to combine effect estimates, and 95% prediction intervals (PIs) were calculated whenever possible. We used the term MHT to encompass ET and EPT, and results are presented for MHT for each outcome, unless otherwise indicated. Sixty systematic reviews were included, involving 102 meta-analyses of RCTs and 38 of observational studies, with 102 unique outcomes. The overall quality of included systematic reviews was moderate to poor. In meta-analyses of RCTs, MHT was beneficial for vasomotor symptoms (frequency: 9 trials, 1,104 women, risk ratio [RR] 0.43, 95% CI 0.33 to 0.57, $p < 0.001$; severity: 7 trials, 503 women, RR 0.29, 95% CI 0.17 to 0.50, $p = 0.002$) and all fracture (30 trials, 43,188 women, RR 0.72, 95% CI 0.62 to 0.84, $p = 0.002$, 95% PI 0.58 to 0.87), as well as vaginal atrophy (intravaginal ET), sexual function, vertebral and nonvertebral fracture, diabetes mellitus, cardiovascular mortality (ET), and colorectal cancer (EPT), but harmful for stroke (17 trials, 37,272 women, RR 1.17, 95% CI 1.05 to 1.29, $p = 0.027$) and venous thromboembolism (23 trials, 42,292 women, RR 1.60, 95% CI 0.99 to 2.58, $p = 0.052$, 95% PI 1.03 to 2.99), as well as cardiovascular disease incidence and recurrence, cerebrovascular disease, nonfatal stroke, deep vein thrombosis, gallbladder disease requiring surgery, and lung cancer mortality (EPT). In meta-analyses of observational studies, MHT was associated with decreased risks of cataract, glioma, and esophageal, gastric, and colorectal cancer, but increased risks of pulmonary embolism, cholelithiasis, asthma, meningioma, and thyroid, breast, and ovarian cancer. ET and EPT had opposite effects for endometrial cancer, endometrial hyperplasia, and Alzheimer disease. The major limitations include the inability to address the varying effects of MHT by type, dose, formulation, duration of use, route of administration, and age of initiation and to take into account the quality of individual studies included in the systematic reviews. The study protocol is publicly available on PROSPERO (CRD42017083412).

Conclusions

MHT has a complex balance of benefits and harms on multiple health outcomes. Some effects differ qualitatively between ET and EPT. The quality of available evidence is only moderate to poor.

Author summary

Why was this study done?

- By 2050, it is estimated that worldwide more than 1.6 billion women will have reached menopause or be postmenopausal, up from 1 billion in 2020.
- Up to 75% of menopausal women are affected by bothersome menopausal symptoms, such as hot flashes and night sweats.

- Menopausal hormone therapy (MHT) is the most effective treatment for alleviating menopausal symptoms, but its effects on numerous health outcomes remain uncertain.

What did the researchers do and find?

- We included 60 published systematic reviews of MHT use in menopausal women, involving 102 meta-analyses of randomized controlled trials and 38 of observational studies, and synthesized the evidence on 102 health outcomes.
- Overall, MHT had a complex balance of benefits and harms; for example, beyond alleviation of menopausal symptoms, it was associated with decreased risks of bone fracture, diabetes mellitus, and esophageal, gastric, and colorectal cancer, but increased risks of stroke, venous thromboembolism, gallbladder disease, and breast and ovarian cancer.
- The available clinical data in support of MHT reducing the risk of coronary heart disease and all-cause mortality in women aged <60 years or within 10 years from menopause (known as the “timing hypothesis”) were only suggestive.
- The overall quality of included systematic reviews was moderate to poor.

What do these findings mean?

- This overview of the evidence landscape could help guideline developers and decision-makers better appreciate the trade-offs between the benefits and harms associated with MHT use in menopausal women.
- More data are needed to evaluate the timing hypothesis for coronary heart disease and all-cause mortality.
- Clinicians should evaluate the scientific strength of systematic reviews prior to considering applying their results in clinical practice.

Introduction

Longevity is increasing worldwide for women. By 2050, the world's women aged 50 years and older are projected to total 1.6 billion, up from 1 billion in 2020 [1]. Natural menopause occurs at a mean age of 49 years [2]. Vasomotor symptoms, including hot flashes and night sweats, are the hallmark symptoms of menopause, affecting approximately 75% of perimenopausal women, and may persist for a decade or longer [3]. In addition, up to 84% of postmenopausal women experience genitourinary symptoms, such as vulvovaginal atrophy and incontinence [4]. The burden of menopausal symptoms can considerably affect the personal, social, and work lives of women [3]. Menopausal hormone therapy (MHT) is the most effective treatment for managing vasomotor and genitourinary symptoms [5,6]. In high-income countries, there were about 600 million woman-years of MHT use in the period 1970–2019, and about 12 million users in the 2010s, of whom 6 million users were in the US and UK alone [7,8].

For several decades, the possible health effects of MHT, beyond alleviation of menopausal symptoms, have been debated. Nevertheless, a systematic, comprehensive assessment in this regard is lacking. More recently, leading medical societies provided clinical practice guidelines for the use of MHT in women [5,6,9–11]. The guidelines lacked consistency regarding some outcomes, such as coronary heart disease (CHD) and all-cause mortality [5,6,9–11]. Often, these guidelines incorporated systematic reviews and meta-analyses as key evidence support for the recommendations, but with little attention to their quality or scientific validity [5,9]. Numerous empirical evaluations have found that poor quality and major flaws impede many published systematic reviews in diverse disciplines [12–18]. In light of the uncertainty surrounding the effects of MHT on numerous health outcomes in women, it is important that the quality of systematic reviews contributing to current guidelines and recommendations be critically appraised in order to provide the highest level and most reliable basis for recommendations in clinical practice. Consequently, we performed an outcome-wide umbrella review to summarize the evidence across existing systematic reviews and meta-analyses on the effects of MHT in perimenopausal and postmenopausal women [19]. We sought to provide a comprehensive overview of the benefits and harms of MHT use, evaluate the validity of effects reported across systematic reviews, assess potential biases in the literature, and examine the credibility of the methods of existing systematic reviews.

Methods

An umbrella review is a review of published systematic reviews, with or without meta-analyses, related to a given topic or question [20–22]. It systematically integrates evidence from multiple systematic reviews to present a comprehensive view of the evidence landscape, readily providing guideline developers and decision-makers with the currently available highest level of evidence relevant to the question posed [21,22]. The protocol for the current umbrella review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42017083412). This study was reported as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [23] ([S1 PRISMA Checklist](#)). Ethical approval was not required for this study.

Literature search and eligibility criteria

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, ISI Web of Science, CINAHL, Google Scholar, Allied and Complementary Medicine Database, Global Health, PsycINFO, CAB International, and WHO Global Health Library from inception to November 26, 2017. No language restriction was applied. Table A in [S1 Text](#) presents the detailed search strategies for each electronic database. Two investigators independently screened the titles and/or abstracts and reviewed full-text articles for eligibility. Any discrepancies were resolved by discussion. References of the included articles were also manually checked to identify additional eligible articles.

Articles were selected for inclusion if they met the following Population, Intervention or Exposure, Comparator, Outcome, Study design (PI[E]COS) criteria: (1) population: perimenopausal or postmenopausal women of any ethnicity in any country or setting; (2) intervention or exposure: any type of MHT, including estrogen-alone therapy (ET) and estrogen plus progestin therapy (EPT), at any dose, duration, and route of administration; (3) comparator: placebo or no treatment; (4) outcome: any health outcome or indicator, including menopausal symptoms; and (5) study design: systematic review, with or without meta-analysis, of randomized controlled trials (RCTs) or observational epidemiological studies (cohort and case-control design). We excluded reviews without a systematic search, systematic reviews that

examined the effects of progestin or selective estrogen receptor modulators (e.g., raloxifene), systematic reviews that compared different types of MHT, and individual participant meta-analyses. If more than 1 systematic review existed on the same scientific question (those with the same PI[E]COS elements), we included the most recent and largest review. In some cases where the largest meta-analysis was not the most recent, we retained the largest and updated it by including the nonoverlapping studies from the most recent review. If the same outcome was investigated in systematic reviews of RCTs and of observational studies or in systematic reviews with different population or intervention/exposure characteristics, all reviews were included for that outcome in order to get a complete picture of the benefits or harms associated with MHT. We categorized outcomes according to the International Classification of Diseases–11th Revision (ICD-11) [24]. We performed an updated search on December 17, 2020, for studies published since November 26, 2017, but the literature obtained did not change the conclusions reached based on the originally included studies. A summary of the literature obtained from the updated search is given in [S2 Text](#).

Data extraction and quality assessment

Two investigators independently extracted data by outcome using a customized data extraction form. For each systematic review, we extracted title of the review, citation details (e.g., author list, journal, year of publication), country, PI(E)COS elements, number of included studies, and meta-analysis method (where applicable). For each individual study included in each meta-analysis, we extracted first author, year of publication, country, study design, phase of prevention, age of participants, menopausal status, type of MHT, route of administration, length of follow-up (where applicable), outcome examined, number of events for binary outcomes or means and standard deviations for continuous outcomes and total number of participants in intervention and control groups in RCTs, number of cases and controls in case-control studies or total population in cohort studies, type of effect estimate (mean difference, standardized mean difference, risk ratio [RR], odds ratio, incidence rate ratio, or hazard ratio), and effect estimate with 95% confidence interval (CI). For systematic reviews without meta-analysis, we abstracted only key findings or conclusions.

Given the issues (e.g., incomplete data, poor data quality) in a sample of included meta-analyses [25–28] as well as the high prevalence of data extraction errors from empirical evaluations [29], we devoted extensive efforts to obtaining and validating the data for the individual studies in each meta-analysis. We developed 2 separate protocols for extracting data from included systematic reviews of RCTs and of observational studies based on the assessment of 5 included reviews [25–28,30] (Figs A and B in [S1 Text](#)). In brief, for meta-analyses of RCTs that provided insufficient or inadequate data for individual studies, the full texts of these studies were retrieved, from which data were extracted. In addition, outcome data from the Women's Health Initiative (WHI) trials were updated based on the most recent publications [31–34]. For meta-analyses of observational studies, we extracted all data from individual studies regardless of the availability of data in the meta-analyses, and then compared these data with the data in the meta-analyses. We verified the inclusion of individual studies in each meta-analysis by checking the eligibility of each study against the PI(E)COS criteria of the meta-analysis, and studies were further excluded if found not to meet the criteria. In a few cases (e.g., no references provided), the review authors were contacted to request additional information.

Two investigators independently assessed the methodological quality of included systematic reviews using the updated 16-item AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews) instrument [35]. Quality appraisal of individual studies is beyond the scope of an

umbrella review. Any discrepancies during data extraction and quality assessment were resolved by discussion or arbitration by a third investigator.

Data synthesis and analysis

We developed a priori an analysis protocol including justification of the statistical methods applied to this umbrella review (S3 Text). In brief, for each meta-analysis we calculated the summary average effect and its 95% CI using the random-effects robust variance estimation method [36]. We quantified the extent of heterogeneity by estimating the between-study standard deviation [37,38]. To further account for heterogeneity, we estimated the predictive distribution for the true effect in a new study [39–42]. The 95% prediction interval (PI) estimates the middle 95% area of the predictive distribution, reflecting the variation in the true effects across study settings, and predicts with 95% confidence the true effect in a new study that is similar to the studies in the meta-analysis [40,43]. Based on simulation results [40,42], the 95% PI was calculated only in meta-analyses of ≥ 10 studies. Next, we examined small-study effects with a random-effects Egger regression [44,45], which assesses whether there is an association between treatment effect size and its standard error. To assess publication bias, we used the Vevea and Hedges selection model [46] and the S-value [47], which represents the severity of publication bias that would hypothetically be required to shift the point estimate to the null. Lastly, for meta-analyses of observational studies, we assessed the robustness of meta-analysis results to potential residual confounding using the E-value [48,49] and its equivalents for meta-analyses [42,50].

The primary analyses focused on the average effects of any type of hormone therapy (ET or EPT). A subgroup analysis by MHT type was conducted to assess whether the effect varied qualitatively between ET and EPT. A qualitative difference means that the effects of ET and EPT do not point in the same direction [51,52]. We use the term MHT to encompass ET and EPT, and results are presented for MHT, unless a qualitative difference was indicated between ET and EPT, in which case results are presented separately for them. We grouped the data according to whether the intervention or exposure was primary or secondary prevention. We defined primary prevention as reducing the risk of occurrence of a disease among individuals who do not have that disease at the beginning of follow-up, and secondary prevention as reducing the severity or progression of a disease among individuals who already have that disease or the risk of recurrence among individuals who have a history of that disease. The analyses were conducted separately for RCTs and observational studies. For observational studies, the analyses were stratified by recency of MHT use (ever, current, or past). Finally, based on the amount and the consistency of the body of evidence, we graded the evidence from meta-analyses as consistent, highly suggestive, suggestive, controversial, or insufficient, following the criteria described in Tables 1 and 2. All estimates were converted to the RR scale [48,53–55], and results are presented on that scale, except where otherwise noted. All statistical analyses were performed using R software (version 4.0.1) [56]. The R scripts are available in S4 and S5 Texts, and the datasets are available at Open Science Framework (<https://osf.io/dsy37/>).

Results

Characteristics of included studies

In total, we identified 10,550 records, scrutinized 160 full-text articles, and ultimately included 60 articles (29 systematic reviews of RCTs [25,26,30,57–82], 27 of observational studies [27,28,83–107], and 4 of both RCTs and observational studies [108–111]) (Fig 1). The studies were published between 1995 and 2017. The 33 systematic reviews of RCTs reported 102 meta-analyses (1 systematic review without meta-analysis), with 81 unique outcomes; the 31

Table 1. Summary of evidence grading for meta-analyses of randomized controlled trials on menopausal hormone therapy and incidence of diseases and other health outcomes.

Evidence	Criteria	Meta-analyses of randomized controlled trials ^a	
		Outcomes with beneficial effects	Outcomes with harmful effects
Consistent	95% CI of the mean effect excludes null value with no heterogeneity, or predictive distribution ^b contains an extreme proportion (>90%) of true effects in the direction of the mean effect	All fracture, vertebral fracture, nonvertebral fracture, colorectal cancer (EPT), cardiovascular mortality (ET)	Cardiovascular disease, cerebrovascular disease, stroke, nonfatal stroke, venous thromboembolism, deep vein thrombosis, gallbladder disease requiring surgery, endometrial hyperplasia (ET), lung cancer mortality (EPT)
Highly suggestive	95% CI of the mean effect excludes null value, with heterogeneity present but predictive distribution not estimable ^c , or predictive distribution contains a substantial proportion (70%–90%) of true effects in the direction of the mean effect	Vasomotor symptoms ^d , vasomotor symptom severity ^d , vaginal atrophy (intra-vaginal ET) ^d , sexual function, urinary incontinence ^d , diabetes mellitus	Cardiovascular disease recurrence
Suggestive	95% CI of the mean effect includes null value, predictive distribution not estimable ^c , and 95% CI of the most precise study ^e excludes null value	Breast cancer (ET), endometrial cancer (EPT), hip fracture (EPT), sleep quality (EPT), skeletal muscle strength (EPT), recurrent urinary tract infection (ET) ^d	Breast cancer (EPT), dementia (EPT), pulmonary embolism (EPT), irregular vaginal bleeding (ET)
Controversial	Predictive distribution contains a non-negligible proportion (>30%) of true effects in both the same and the opposite direction of the mean effect	None	None
Insufficient	Insufficient evidence to draw conclusions	All-cause mortality, all cancer incidence and mortality, lung cancer incidence and mortality (ET), breast cancer recurrence and mortality, ovarian cancer incidence and overall survival, endometrial cancer (ET), colorectal cancer incidence (ET) and mortality, cardiovascular mortality (EPT), cerebrovascular disease recurrence, stroke recurrence, fatal stroke incidence and recurrence, nonfatal stroke recurrence, transient ischemic attack incidence and recurrence, coronary heart disease incidence and recurrence and mortality, myocardial infarction incidence and recurrence, fatal and nonfatal myocardial infarction incidence and recurrence, angina pectoris incidence and recurrence, cardiac death, coronary revascularization, venous thromboembolism recurrence, deep vein thrombosis recurrence, pulmonary embolism incidence (ET) and recurrence, dementia (ET), Alzheimer disease, cognitive function (in healthy women and in women with dementia), hip fracture (ET), endometrial hyperplasia (EPT), irregular vaginal bleeding (EPT), sleep quality (ET), occurrence and recurrence of depressive symptoms	

Small-study effects existed for all fracture, sexual function, urinary incontinence, and deep vein thrombosis; the Egger regression test was used to examine whether smaller studies tended to show more pronounced effects than larger studies; it was applied only in meta-analyses of ≥ 10 studies; more information is available in [S3 Text](#). Meta-analysis results were robust to severe or extreme publication bias for all fracture, vasomotor symptoms, stroke, nonfatal stroke, venous thromboembolism, gallbladder disease requiring surgery, and endometrial hyperplasia (ET); “robust to severe or extreme publication bias” means that the meta-analysis results cannot be explained away by hypothetical publication bias that greatly exceeds empirical estimates of publication bias severity in medicine (i.e., hypothetical publication bias in which statistically significant positive effects are 4-fold more likely to be published and meta-analyzed than nonsignificant or negative effects); more information is available in [S3 Text](#). CI, confidence interval; EPT, estrogen plus progestin therapy; ET, estrogen-alone therapy.

^aThe average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or postmenopausal women. When subgroup analysis by type of hormone therapy indicated a qualitative difference or statistically significant results were found for only 1 type of hormone therapy, results are presented separately for them. The effects refer to outcome incidence, unless otherwise indicated.

^bThe predictive distribution describes how the true effect sizes across studies are distributed around the summary average effect. Predictive distribution was estimated only in meta-analyses of ≥ 10 studies. More information is available in [S3 Text](#).

^cDue to a small number of studies (<10) being included in the meta-analysis.

^dIn women who already have the outcome of interest.

^eThe study with the smallest standard error in each meta-analysis.

<https://doi.org/10.1371/journal.pmed.1003731.t001>

systematic reviews of observational studies reported 38 meta-analyses (2 systematic reviews without meta-analysis), with 40 unique outcomes; 19 outcomes overlapped between meta-analyses of RCTs and of observational studies, and thus in total 102 unique outcomes were reported across all included systematic reviews. Characteristics of the included systematic reviews for each outcome are summarized in Tables B and C in [S1 Text](#).

Table 2. Summary of evidence grading for meta-analyses of observational epidemiological studies on menopausal hormone therapy and incidence of diseases and other health outcomes.

Evidence	Criteria	Meta-analyses of observational epidemiological studies ^a	
		Outcomes with beneficial effects	Outcomes with harmful effects
Consistent	95% CI of the mean effect excludes null value with no heterogeneity, or predictive distribution ^b contains an extreme proportion (>90%) of true effects in the direction of the mean effect	Esophageal cancer, gastric cancer, colorectal cancer, breast-cancer-specific survival ^c , breast cancer overall survival ^c , ovarian cancer overall survival ^d , Alzheimer disease (ET), cataract, coronary heart disease, all-cause mortality	Breast cancer (EPT), endometrial cancer (ET), Alzheimer disease (EPT), venous thromboembolism, deep vein thrombosis, pulmonary embolism, cholelithiasis, asthma
Highly suggestive	95% CI of the mean effect excludes null value, with heterogeneity present but predictive distribution not estimable ^e , or predictive distribution contains a substantial proportion (70%–90%) of true effects in the direction of the mean effect	Glioma	Breast cancer (ET), ovarian cancer, meningioma, thyroid cancer
Suggestive	95% CI of the mean effect includes null value, predictive distribution not estimable ^e , and 95% CI of the most precise study ^f excludes null value	Breast cancer recurrence ^d , lung cancer overall survival ^g , diabetes mellitus, coronary heart disease mortality, cardiovascular disease incidence and mortality	Cutaneous melanoma (ET), endometrial cancer (EPT), systemic lupus erythematosus, Parkinson disease
Controversial	Predictive distribution contains a non-negligible proportion (>30%) of true effects in both the same and the opposite direction of the mean effect	Breast cancer mortality, pancreatic cancer, lung cancer	
Insufficient	Insufficient evidence to draw conclusions	Primary liver cancer, endometrial cancer mortality, ovarian cancer recurrence, head and neck cancer, cutaneous melanoma (EPT), osteoarthritis, dementia	

Small-study effects existed for breast-cancer-specific survival, breast cancer overall survival, and glioma; the Egger regression test was used to examine whether smaller studies tended to show more pronounced effects than larger studies; it was applied only in meta-analyses of ≥ 10 studies; more information is available in [S3 Text](#). Meta-analysis results were robust to severe or extreme publication bias for esophageal cancer, gastric cancer, colorectal cancer, breast cancer (EPT), breast cancer (ET), breast-cancer-specific survival, breast cancer overall survival, endometrial cancer (ET), ovarian cancer incidence and overall survival, coronary heart disease, venous thromboembolism, asthma, and cholelithiasis; “robust to severe or extreme publication bias” means that the meta-analysis results cannot be explained away by hypothetical publication bias that greatly exceeds empirical estimates of publication bias severity in medicine (i.e., hypothetical publication bias in which statistically significant positive effects are 4-fold more likely to be published and meta-analyzed than nonsignificant or negative effects); more information is available in [S3 Text](#). CI, confidence interval; EPT, estrogen plus progestin therapy; ET, estrogen-alone therapy.

^aThe average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or postmenopausal women. When subgroup analysis by type of hormone therapy indicated a qualitative difference or statistically significant results were found for only 1 type of hormone therapy, results are presented separately for them. The effects refer to outcome incidence, unless otherwise indicated.

^bThe predictive distribution describes how the true effect sizes across studies are distributed around the summary average effect. Predictive distribution was estimated only in meta-analyses of ≥ 10 studies. More information is available in [S3 Text](#).

^cUse of menopausal hormone therapy before or after diagnosis of cancer.

^dUse of menopausal hormone therapy after diagnosis of cancer.

^eDue to a small number of studies (<10) being included in the meta-analysis.

^fThe study with the smallest standard error in each meta-analysis.

^gUse of menopausal hormone therapy before diagnosis of cancer.

<https://doi.org/10.1371/journal.pmed.1003731.t002>

Quality assessment of included studies

For the 7 AMSTAR 2 critical domains, 36% of the included systematic reviews established a priori a protocol for the review, 59% performed a comprehensive literature search, 34% provided a list of excluded studies with justification, 78% used a satisfactory technique for assessing the risk of bias in individual studies, 47% used the random-effects model for meta-analysis, 47% discussed the impact of risk of bias in individual studies in the interpretation of the results of the review, and 29% performed graphical or statistical tests for publication bias and discussed the likelihood and magnitude of impact of publication bias. [Fig 2](#) presents a summary




Fig 1. Flow chart for study selection process. MHT, menopausal hormone therapy; OE, observational epidemiological study; RCT, randomized controlled trial.

<https://doi.org/10.1371/journal.pmed.1003731.g001>

of quality assessment by outcome across all included systematic reviews. Each AMSTAR 2 domain judgment for each outcome is available in Tables D and E in [S1 Text](#).

Benefits and harms of MHT

In total, we included 936 individual study estimates from RCTs and 380 from observational studies (190 from case-control and 190 from cohort studies) for meta-analysis. The median number of study estimates per outcome in meta-analyses of RCTs and of observational studies was 5 (range 1–55) and 7 (range 1–71), respectively. Tables 1 and 2 summarize the evidence for all disease outcomes (both primary and secondary prevention) from meta-analyses of RCTs and of observational studies, respectively. The surrogate outcomes with consistent or highly suggestive evidence from meta-analyses of RCTs are summarized in Fig C in [S1 Text](#).




Fig 2. Quality assessment by outcome presented as percentages across all included systematic reviews. PI(E)CO, Population, Intervention or Exposure, Comparator, Outcome; RoB, risk of bias.

<https://doi.org/10.1371/journal.pmed.1003731.g002>

Consistent or highly suggestive evidence means that the 95% CI of the summary average effect excludes the null or the estimated predictive distribution contains a substantial proportion ($\geq 70\%$) of true effects in the direction of the average effect (Tables 1 and 2). More detailed results are available in Tables F to X in [S1 Text](#). Below we described the meta-analysis results for only outcomes with consistent or highly suggestive evidence (Figs 3 and 4, and Fig C in [S1 Text](#)). The meta-analysis results for other evidence levels, as well as small-study effects, publication bias, and sensitivity analysis for residual confounding in observational studies, are described in [S1 Text](#).




Fig 3. Consistent or highly suggestive evidence from meta-analyses of randomized controlled trials on menopausal hormone therapy and incidence of diseases and other health outcomes. The average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or postmenopausal women, unless otherwise stated. All estimates are from our own analysis apart from diabetes mellitus. Subgroup analysis results by type of menopausal hormone therapy can be found in Tables F to K in *S1 Text*. The center of each square represents the summary average effect for each outcome, and the horizontal line represents the corresponding 95% CI. CI, confidence interval; EPT, estrogen plus progestin therapy; ET, estrogen-alone therapy; NA, not available or not applicable. ^aIn women who already have the outcome of interest. ^bThe effect measures for continuous outcomes were converted into the risk ratio scale for comparison; the results in original scale can be found in Tables F and I in *S1 Text*.

<https://doi.org/10.1371/journal.pmed.1003731.g003>

Neoplasms. In RCTs, EPT was associated with a decreased risk of colorectal cancer (5 trials, 24,624 women, RR 0.79, 95% CI 0.64 to 0.98, $p = 0.045$), but an increased risk of lung cancer mortality (3 trials, 19,513 women, RR 1.10, 95% CI 1.00 to 1.21, $p = 0.047$). In observational studies, MHT was associated with decreased risks of glioma (10 studies, 1,580,830 women, RR 0.87, 95% CI 0.72 to 1.04, $p = 0.11$, 95% PI 0.57 to 1.21), esophageal cancer (5 studies, 203,548 women, RR 0.70, 95% CI 0.60 to 0.81, $p = 0.009$), gastric cancer (6 studies, 616,630 women, RR 0.78, 95% CI 0.70 to 0.86, $p = 0.003$), and colorectal cancer (25 studies, 527,776 women, RR 0.83, 95% CI 0.77 to 0.89, $p < 0.001$, 95% PI 0.57 to 1.06). Among women with a history of breast cancer, both pre- and post-diagnosis MHT use was associated with improved breast-cancer-specific survival (11 studies, 24,753 women, RR 0.72, 95% CI 0.59 to 0.88, $p = 0.006$, 95% PI 0.48 to 0.93) and breast cancer overall survival (16 studies, 39,593 women, RR 0.82, 95% CI 0.75 to 0.89, $p < 0.001$, 95% PI 0.59 to 1.06), and among women with a history of ovarian cancer, post-diagnosis MHT use was associated with improved ovarian cancer overall survival (3 studies, 599 women, RR 0.81, 95% CI 0.71 to 0.91, $p = 0.025$). On the




Fig 4. Consistent or highly suggestive evidence from meta-analyses of observational epidemiological studies on menopausal hormone therapy and incidence of diseases and other health outcomes. The average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or postmenopausal women, unless otherwise stated. The estimates are for ever use of menopausal hormone therapy, unless otherwise stated. All estimates are from our own analysis. Subgroup analysis results by type and recency of menopausal hormone therapy use can be found in Tables L to Q in [S1 Text](#). The center of each square represents the summary average effect for each outcome, and the horizontal line represents the corresponding 95% CI. Cc, case-control study; CI, confidence interval; Co, cohort study; EPT, estrogen plus progestin therapy; ET, estrogen-alone therapy; NA, not available or not applicable. ^aCurrent use of menopausal hormone therapy. ^bUse of menopausal hormone therapy before or after diagnosis of cancer. ^cUse of menopausal hormone therapy after diagnosis of cancer.

<https://doi.org/10.1371/journal.pmed.1003731.g004>

other hand, MHT was associated with increased risks of meningioma (13 studies, 1,479,871 women, RR 1.14, 95% CI 0.98 to 1.33, $p = 0.076$, 95% PI 0.61 to 1.59), thyroid cancer (12 studies, 802,681 women, RR 1.09, 95% CI 0.88 to 1.34, $p = 0.36$, 95% PI 0.82 to 1.44), ovarian cancer (37 studies, 2,389,636 women, RR 1.16, 95% CI 1.06 to 1.26, $p = 0.002$, 95% PI 0.71 to 1.54), and breast cancer (71 studies, 3,331,883 women, RR 1.25, 95% CI 1.19 to 1.31, $p < 0.001$, 95% PI 0.93 to 1.74; Table L in [S1 Text](#)). No qualitative difference in breast cancer risk between ET and EPT was found ([Fig 4](#)). In women with a uterus, ET was associated with an increased risk

of endometrial cancer (18 studies, 836,988 women, RR 2.55, 95% CI 2.05 to 3.18, $p < 0.001$, 95% PI 1.01 to 6.99).

Diseases of the circulatory system. In RCTs, MHT was associated with increased risks of venous thromboembolism (23 trials, 42,292 women, RR 1.60, 95% CI 0.99 to 2.58, $p = 0.052$, 95% PI 1.03 to 2.99) and deep vein thrombosis (14 trials, 38,923 women, RR 1.39, 95% CI 0.68 to 2.84, $p = 0.19$, 95% PI 1.01 to 2.38). No evidence of effect was found with regard to CHD incidence (17 trials, 39,448 women, RR 1.02, 95% CI 0.82 to 1.26, $p = 0.75$; Table F in [S1 Text](#)) and recurrence (8 trials, 5,045 women, RR 0.97, 95% CI 0.76 to 1.24, $p = 0.65$; Table I in [S1 Text](#)). In observational studies, MHT was associated with a decreased risk of CHD (10 studies, 91,067 women, RR 0.82, 95% CI 0.69 to 0.96, $p = 0.021$, 95% PI 0.69 to 1.14), but increased risks of venous thromboembolism (4 studies, 123,376 women, RR 1.99, 95% CI 1.53 to 2.58, $p = 0.006$), deep vein thrombosis (3 studies, 11,055 women, RR 2.26, 95% CI 1.14 to 4.49, $p = 0.038$), and pulmonary embolism (3 studies, 122,745 women, RR 2.05, 95% CI 1.49 to 2.83, $p = 0.017$).

Genitourinary system. In RCTs, MHT was associated with improved vasomotor symptoms (frequency: 9 trials, 1,104 women, RR 0.43, 95% CI 0.33 to 0.57, $p < 0.001$; severity: 7 trials, 503 women, RR 0.29, 95% CI 0.17 to 0.50, $p = 0.002$) and urinary incontinence (13 trials, 16,999 women, RR 0.82, 95% CI 0.62 to 1.09, $p = 0.15$, 95% PI 0.36 to 1.94). Intravaginal ET was associated with improved vaginal atrophy (5 trials, 1,903 women, RR 0.31, 95% CI 0.12 to 0.81, $p = 0.03$). On the other hand, oral ET was associated with an increased risk of endometrial hyperplasia (13 trials, 3,884 women, RR 6.93, 95% CI 2.07 to 23.23, $p = 0.007$, 95% PI 1.18 to 50.68).

Functioning assessment. In RCTs, MHT was associated with improved sexual function (measured by a composite score of arousal and sexual interest, orgasm, and pain) (10 trials, 2,826 women, RR 0.82, 95% CI 0.71 to 0.96, $p = 0.017$, 95% PI 0.57 to 1.28).

Bone loss and fracture. In RCTs, MHT was associated with increased bone mineral density at lumbar spine, forearm, femoral neck, and proximal femur (Fig C in [S1 Text](#)), and decreased risks of all fracture (30 trials, 43,188 women, RR 0.72, 95% CI 0.62 to 0.84, $p = 0.002$, 95% PI 0.58 to 0.87), vertebral fracture (16 trials, 34,336 women, RR 0.69, 95% CI 0.50 to 0.94, $p = 0.033$), and nonvertebral fracture (26 trials, 25,921 women, RR 0.76, 95% CI 0.62 to 0.94, $p = 0.025$, 95% PI 0.60 to 1.02).

Diseases of the nervous system. In RCTs, MHT was associated with increased risks of cerebrovascular disease (21 trials, 42,281 women, RR 1.25, 95% CI 1.04 to 1.50, $p = 0.03$), stroke (17 trials, 37,272 women, RR 1.17, 95% CI 1.05 to 1.29, $p = 0.027$), and nonfatal stroke (11 trials, 32,656 women, RR 1.35, 95% CI 1.08 to 1.69, $p = 0.025$). In observational studies, ET was associated with a decreased risk of Alzheimer disease (10 studies, 8,419 women, RR 0.76, 95% CI 0.60 to 0.96, $p = 0.028$, 95% PI 0.56 to 1.03), while EPT was associated with an increased risk (2 studies, 3,186 women, RR 1.42, 95% CI 1.24 to 1.62, $p = 0.02$).

Diseases of the visual system. In observational studies, MHT was associated with a decreased risk of cataract (7 studies, 43,082 women, RR 0.87, 95% CI 0.79 to 0.97, $p = 0.022$).

Diseases of the respiratory system. In observational studies, MHT was associated with an increased risk of asthma (5 studies, 163,161 women, RR 1.41, 95% CI 1.09 to 1.81, $p = 0.023$).

Diseases of the digestive system. In RCTs, MHT was associated with an increased risk of gallbladder disease requiring surgery (5 trials, 26,526 women, RR 1.63, 95% CI 1.31 to 2.04, $p = 0.011$). In observational studies, MHT was associated with an increased risk of cholelithiasis (8 studies, 277,380 women, RR 1.63, 95% CI 1.41 to 1.88, $p < 0.001$).

Endocrine, nutritional, and metabolic diseases. In RCTs, MHT was associated with lower levels of fasting glucose and fasting insulin and reduced insulin resistance in women

with and without diabetes mellitus (Fig C in [S1 Text](#)), and a decreased risk of developing diabetes mellitus (RR 0.70, 95% CI 0.60 to 0.90; Table X in [S1 Text](#)). In addition, MHT was associated with lower levels of low-density lipoprotein cholesterol (LDL-C), lipoprotein(a), and plasminogen activator inhibitor-1 (PAI-1), but higher levels of triglycerides and C-reactive protein (Fig C in [S1 Text](#)).

Other diseases not elsewhere classified. In RCTs, MHT was associated with increased risks of cardiovascular disease incidence (22 trials, 39,080 women, RR 1.29, 95% CI 0.99 to 1.68, $p = 0.056$, 95% PI 1.02 to 1.61) and recurrence (11 trials, 5,922 women, RR 1.08, 95% CI 0.94 to 1.25, $p = 0.18$, 95% PI 0.94 to 1.27), while ET was associated with a small reduction in cardiovascular mortality (3 trials, 11,081 women, RR 0.97, 95% CI 0.95 to 0.99, $p = 0.039$). In observational studies, MHT was associated with a decreased risk of all-cause mortality (6 studies, 106,642 women, RR 0.89, 95% CI 0.82 to 0.97, $p = 0.029$), but no evidence of effect was found in RCTs (38 trials, 47,757 women, RR 0.99, 95% CI 0.83 to 1.18, $p = 0.72$; Table F in [S1 Text](#)).

Discussion

Summary of key findings

In this umbrella review, consistent or highly suggestive evidence from RCTs found that MHT was beneficial for vasomotor symptoms, vaginal atrophy (intravaginal ET), sexual function, all fracture, vertebral and nonvertebral fracture, diabetes mellitus, cardiovascular mortality (ET), and colorectal cancer (EPT), but harmful for cardiovascular disease incidence and recurrence, cerebrovascular disease, stroke, nonfatal stroke, venous thromboembolism, deep vein thrombosis, gallbladder disease requiring surgery, and lung cancer mortality (EPT). Consistent or highly suggestive evidence from observational studies found that MHT was associated with decreased risks of cataract, glioma, and esophageal, gastric, and colorectal cancer, but increased risks of venous thromboembolism, deep vein thrombosis, pulmonary embolism, cholelithiasis, asthma, meningioma, and thyroid, breast, and ovarian cancer. The effects of ET and EPT differed qualitatively for endometrial cancer, endometrial hyperplasia, and Alzheimer disease. The evidence levels for the other disease outcomes ranged from suggestive to insufficient.

Limitations

Certain limitations need to be taken into account in the interpretation of our findings. First, umbrella reviews focus on existing systematic reviews, and therefore outcomes not assessed in a systematic review cannot be included. Second, the studies identified in the updated search in 2020 were not included in the umbrella review. This evidence analysis will be taken into account in the future when the current umbrella review is updated. Third, we were unable to take into account the quality of the individual studies included in the systematic reviews. Quality appraisal of individual studies is not the focus of umbrella reviews, as included systematic reviews are expected to perform this task. However, as discussed later, included systematic reviews are generally limited in their usefulness for accurate rating of quality of evidence. Fourth, it can be expected that the effects of MHT may vary between participants (e.g., based on age or time since menopause) and treatments (MHT type, dose, formulation, duration of use, and route of administration). Due to data unavailability, however, we were unable to address varying effects based on these prognostic factors, particularly for the commonly used MHT formulations (e.g., estradiol and micronized progesterone). Instead, we used the predictive distribution (e.g., 95% PI) to estimate the range of effects across study settings [40–42]. Thus, the random-effects average effect should be interpreted in conjunction with the

predictive distribution and the effect from the subset of studies most relevant to the patients needed to treat [112,113]. Further systematic reviews or umbrella reviews of comparative evidence (e.g., head-to-head randomized trials) on different prognostic factors are warranted.

Breast and ovarian cancer

In observational studies, we found that both ET and EPT were associated with increased incidence of breast and ovarian cancer. Our findings are consistent with those of 2 recent individual participant meta-analyses of the worldwide epidemiological evidence [7,8]. However, among women with a history of breast or ovarian cancer, pre- or post-diagnosis MHT use was associated with improved cancer-specific or overall survival. The findings were further replicated by 2 recent prospective cohort studies [114,115]. One possible explanation for these findings could be that women who used MHT after diagnosis were likely to have used MHT before diagnosis. Therefore, despite increased incidence of breast and ovarian cancer with MHT use, MHT users with established breast and ovarian tumors may have better prognosis than nonusers [114,115]. Observational data on MHT and breast cancer mortality were controversial. Subgroup analysis by MHT type did not account for the divergent results. Data from the Million Women Study recently showed that both ET and EPT were associated with increased breast cancer mortality [116]. It is therefore difficult to interpret the discrepancy in these results, but one speculation could be that any causal effect of MHT on breast cancer survival may reasonably result in such divergent results, since mortality reflects the net effects of MHT on both incidence and survival [117]. Nevertheless, it is unclear whether the inverse association between MHT and breast cancer survival is causal or due to residual confounding or other biases. In our analysis, small-study effects were also present. Furthermore, the HABITS (Hormonal Replacement Therapy after Breast Cancer—Is It Safe?) trial [118,119], which compared MHT for menopausal symptoms with symptomatic treatment without MHT among women with a history of breast cancer, found an increased risk of breast cancer recurrence following MHT. The HABITS trial was therefore terminated early [118], along with the Stockholm trial [120,121], in which, however, no evidence of increased breast cancer recurrence with MHT was found. Current guidelines [5,11,122] suggest that, in women with a history of breast cancer, systemic MHT is generally not recommended for alleviating vasomotor symptoms, and low-dose vaginal ET may be an option to manage genitourinary symptoms after nonhormonal therapies or complementary options have been unsuccessful and after a detailed discussion of risks and benefits and review with an oncologist. In all, given the paucity of data from RCTs and the potential biases in the observational evidence, further well-designed longitudinal studies of MHT use in women with a history of breast or ovarian cancer across different settings, while controlling for different sources of bias, are warranted to assess causality.

In the WHI trials, a qualitative difference was found in the effects of ET and EPT on breast cancer incidence, with ET decreasing but EPT increasing the risk [31]. ET was also found to be associated with lower breast cancer mortality, whereas no evidence of effect was observed for EPT [31]. Several explanations were proposed to reconcile the discordance between the WHI trials and observational studies: older women in the WHI trials, confounding in observational studies, different biological mechanisms of ET and EPT, or simply the play of chance in the WHI trials [8,31]. Given the extensive amount of epidemiological evidence, replication of the findings from the WHI trials should be undertaken.

CHD and all-cause mortality

The effects of MHT on CHD and all-cause mortality have long been debated [90,123–128]. In our analysis, observational data consistently showed up to 18% lower risk of CHD and up to

11% lower risk of all-cause mortality with ever use of MHT, while RCTs failed to support the presence of these beneficial effects. The distinction in populations of women between RCTs and observational studies—i.e., that observational studies generally included younger women who started MHT around the time of menopause—has led to the well-known “timing hypothesis” [123,124]. According to this hypothesis, MHT reduces CHD and all-cause mortality only when initiated close to the onset of menopause, but does not reduce or even increases CHD and all-cause mortality when initiated many years later [123,124]. Indeed, the age-stratification analyses from the WHI trials found that MHT reduced CHD and all-cause mortality in women aged 50–59 years, but increased CHD in older women [33,34]. Four meta-analyses of RCTs assessed the timing hypothesis by stratifying trials according to mean time since menopause or mean age of participants at baseline, showing a highly significant reduction in CHD and all-cause mortality in women aged <60 years or those <10 years from menopause, but not in older women [60,76,99,129]. The literature reviews widely adopted the WHI trials and the meta-analyses as part of the evidence supporting the beneficial effects of MHT in the younger group of women [123–126]. The results were further carried into current guidelines [5,9,11]. However, it is worth noting that all these analyses are by nature post hoc, and such subgroup results are most appropriately regarded as hypothesis generation rather than hypothesis confirmation due to multiple comparisons [10,128,130,131]. Particularly for the meta-analyses, because of issues of potential confounding and ecological fallacy [132,133], findings of such study-level analyses have to be interpreted cautiously. On the other hand, we did not find evidence that MHT caused additional events in women (mean baseline age \geq 60 years) with established CHD.

ELITE (Early versus Late Intervention Trial with Estradiol) [134], the first trial specifically designed to test the timing hypothesis, found that oral estradiol reduced the progression of subclinical atherosclerosis (measured as carotid-artery intima-media thickness) when initiated within 6 years after menopause, but not when initiated \geq 10 years after menopause. It is unclear whether this favorable effect on atherosclerosis will translate into a reduction in risk of CHD [128]. In addition, the Kronos Early Estrogen Prevention Study (KEEPS) [135], a RCT of MHT in recently menopausal women (within 3 years after menopause), found no evidence of effect of oral conjugated equine estrogens or transdermal 17 β -estradiol on the progression of carotid-artery intima-media thickness or coronary artery calcium. Mendelian randomization studies have demonstrated that several plasma biomarkers (e.g., LDL-C) have a causal role in CHD [136–140]. Among these biomarkers, however, we found that the effects of MHT were mixed, with MHT reducing LDL-C, lipoprotein(a), and PAI-1, but increasing triglycerides. Overall, the available clinical data in support of the beneficial effects of MHT on CHD and all-cause mortality as well as the timing hypothesis are only suggestive. Current guidelines [5,6,10,11] suggest that for menopausal women with low cardiovascular risk and no contraindications, MHT could be considered for treatment of bothersome vasomotor symptoms and prevention of bone loss or fracture for those at elevated risk, but not for primary prevention of cardiovascular diseases. More clinical as well as biological data are needed to confirm or refute the timing hypothesis.

Urinary incontinence

The WHI trials found that oral ET or EPT increased the risk of urinary incontinence among continent women [141]. The 2012 Cochrane review [63] included 13 RCTs, comprising 10 small studies and 3 large studies, to assess the efficacy of MHT in treating urinary incontinence. Four small studies used intravaginal ET, while the rest used oral ET or EPT. Based on post hoc subgroup analysis, the review concluded that intravaginal ET may improve

incontinence, while oral ET or EPT may worsen incontinence. Though qualitative differences between different routes of administration are generally not expected [51], this result was nevertheless carried into the guidelines without caveats [5,9]. In our analysis, small-study effects were very prominent: All 10 small studies, regardless of route of administration, pointed in the direction of beneficial effects, while the 3 large studies reported harmful effects. Taken together, current evidence shows that oral MHT increases the risk of urinary incontinence and worsens incontinence in postmenopausal women. The opposite effects of systemic and local MHT should be viewed at best as exploratory.

Credibility of meta-analyses

We found major methodological limitations in a substantial proportion of included meta-analyses, some of which warrant further discussion. First, a fixed-effect meta-analysis model, instead of a random-effects model, was often used, even when heterogeneity was present or anticipated a priori. The fixed-effect model assumes that all studies in the meta-analysis share a common true effect size, whereas the random-effects model assumes that there is a distribution of true effect sizes [142]. By gathering studies from the published literature, the random-effects assumption is the only plausible match to the underlying effect distribution [142]. Second, when a random-effects model was used, the summary effect was often incorrectly interpreted as an estimate of a common effect, as under a fixed-effect model. Under the random-effects model, the summary effect is an estimate of the mean of a distribution of true effects across studies [112,113,142]. Third, investigators often relied heavily on statistical methods (e.g., the Egger test) to deal with publication bias. To address publication bias, there is a need to obtain a representative sample of studies on a topic (e.g., through comprehensive literature searches). Fourth, the tools used for risk of bias assessment of individual studies were generally not comprehensive, and risk of bias was often evaluated by study across outcomes rather than by outcome across studies, which limited the quality of evidence rating in existing meta-analyses.

In conclusion, MHT has a complex balance of benefits and harms on various health outcomes. Some effects differ qualitatively between ET and EPT. Decisions regarding the use of MHT should consider the full range of effects, along with patients' values and preferences. The overall quality of existing systematic reviews is moderate to poor. Clinicians should evaluate their scientific strength prior to considering applying their results in clinical practice.

Supporting information

S1 PRISMA Checklist. (DOCX)

S1 Text. Search strategy, study characteristics, data extraction protocols, quality assessment, and analysis results (heterogeneity, publication bias, etc.). Results: Supplementary results for umbrella review on menopausal hormone therapy and women's health. Table A: Search strategies used to retrieve papers from different databases. Table B: Characteristics of included systematic reviews and/or meta-analyses of randomized controlled trials on menopausal hormone therapy and multiple outcomes. Table C: Characteristics of included systematic reviews and/or meta-analyses of observational epidemiological studies on menopausal hormone therapy and multiple outcomes. Table D: Quality assessment of included systematic reviews and/or meta-analyses of randomized controlled trials on menopausal hormone therapy and multiple outcomes. Table E: Quality assessment of included systematic reviews and/or meta-analyses of observational epidemiological studies on menopausal hormone therapy and

multiple outcomes. Table F: Any menopausal hormone therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table G: Estrogen-alone therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table H: Estrogen plus progestin therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table I: Any menopausal hormone therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table J: Estrogen-alone therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table K: Estrogen plus progestin therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table L: Any menopausal hormone therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table M: Estrogen-alone therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table N: Estrogen plus progestin therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table O: Any menopausal hormone therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table P: Estrogen-alone therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table Q: Estrogen plus progestin therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table R: Assessment of small-study effects and publication bias: Any menopausal hormone therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table S: Assessment of small-study effects and publication bias: Any menopausal hormone therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of randomized controlled trials. Table T: Assessment of small-study effects and publication bias: Any menopausal hormone therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table U: Sensitivity analysis for residual confounding: Any menopausal hormone therapy for primary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table V: Assessment of small-study effects and publication bias: Any menopausal hormone therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table W: Sensitivity analysis for residual confounding: Any menopausal hormone therapy for secondary prevention of multiple outcomes in included systematic reviews and meta-analyses of observational epidemiological studies. Table X: Summary of results for outcomes with no available data for meta-analysis. Fig A: Prespecified protocol for extracting data from included systematic reviews and/or meta-analyses of randomized controlled trials on menopausal hormone therapy and multiple outcomes. Fig B: Prespecified protocol for extracting data from included systematic reviews and/or meta-analyses of observational epidemiological studies on menopausal hormone therapy and multiple outcomes. Fig C: Consistent or highly suggestive evidence from meta-analyses of randomized controlled trials on menopausal hormone therapy and multiple surrogate outcomes. Fig D: Suggestive evidence from meta-analyses of randomized controlled trials on menopausal hormone therapy and incidence of diseases and other health outcomes. Fig E: Suggestive evidence from meta-analyses of observational epidemiological studies on menopausal hormone therapy

and incidence of diseases and other health outcomes.
(PDF)

S2 Text. Updated database search, from November 27, 2017, to December 17, 2020.

Table A: Characteristics of systematic reviews and/or meta-analyses on menopausal hormone therapy and multiple outcomes, updated on December 17, 2020. Fig A: Flow chart for study selection process, updated on December 17, 2020.
(PDF)

S3 Text. Statistical analysis protocol.

(PDF)

S4 Text. R scripts for meta-analyses of randomized controlled trials.

(PDF)

S5 Text. R scripts for meta-analyses of observational epidemiological studies.

(PDF)

Acknowledgments

We would like to thank the Biomedical Library at University of Gothenburg for retrieving the full-text articles. We also thank Sarah M. Greising (University of Minnesota, US), Mohammad Hassan Murad (Mayo Clinic, US), and James M. Whedon (Southern California University of Health Sciences, US) for providing additional data or information. We thank Muwada Bashir Awad Bashir (University of Gothenburg, Sweden) for assistance with data extraction, and Yarong Tian (University of Gothenburg, Sweden) for advice on drawing figures. They were not compensated for their contribution.

Author Contributions

Conceptualization: Guo-Qiang Zhang, Siew Hwa Lee, Bright I. Nwaru.

Data curation: Guo-Qiang Zhang, Jin-Liang Chen, Ying Luo, Panagiotis Anagnostis, Ulugbek Nurmatov, Madar Talibov, Jing Zhang, Siew Hwa Lee, Bright I. Nwaru.

Formal analysis: Guo-Qiang Zhang, Jin-Liang Chen, Ying Luo, Maya B. Mathur, Panagiotis Anagnostis, Ulugbek Nurmatov, Madar Talibov, Jing Zhang, Catherine M. Hawrylowicz, Mary Ann Lumsden, Hilary Critchley, Aziz Sheikh, Bo Lundbäck, Cecilia Lässer, Hannu Kankaanranta, Siew Hwa Lee, Bright I. Nwaru.

Funding acquisition: Bo Lundbäck, Bright I. Nwaru.

Investigation: Guo-Qiang Zhang, Jin-Liang Chen, Ying Luo, Maya B. Mathur, Panagiotis Anagnostis, Ulugbek Nurmatov, Madar Talibov, Jing Zhang, Catherine M. Hawrylowicz, Mary Ann Lumsden, Hilary Critchley, Aziz Sheikh, Bo Lundbäck, Cecilia Lässer, Hannu Kankaanranta, Siew Hwa Lee, Bright I. Nwaru.

Methodology: Guo-Qiang Zhang, Maya B. Mathur, Bright I. Nwaru.

Project administration: Guo-Qiang Zhang, Bright I. Nwaru.

Resources: Bright I. Nwaru.

Software: Guo-Qiang Zhang, Maya B. Mathur.

Supervision: Bo Lundbäck, Cecilia Lässer, Hannu Kankaanranta, Bright I. Nwaru.

Validation: Guo-Qiang Zhang, Jin-Liang Chen, Ying Luo, Maya B. Mathur, Panagiotis Anagnostis, Jing Zhang, Bright I. Nwaru.

Visualization: Guo-Qiang Zhang, Maya B. Mathur, Hannu Kankaanranta, Bright I. Nwaru.

Writing – original draft: Guo-Qiang Zhang, Bright I. Nwaru.

Writing – review & editing: Guo-Qiang Zhang, Jin-Liang Chen, Ying Luo, Maya B. Mathur, Panagiotis Anagnostis, Ulugbek Nurmatov, Madar Talibov, Jing Zhang, Catherine M. Hawrylowicz, Mary Ann Lumsden, Hilary Critchley, Aziz Sheikh, Bo Lundbäck, Cecilia Lässer, Hannu Kankaanranta, Siew Hwa Lee, Bright I. Nwaru.

References

1. United Nations Population Division. World population prospects 2019. New York: United Nations Population Division; 2020 [cited 2020 Nov 27]. Available from: <https://population.un.org/wpp/DataQuery/>.
2. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. *Int J Epidemiol*. 2014; 43(5):1542–62. <https://doi.org/10.1093/ije/dyu094> PMID: 24771324
3. Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause—global prevalence, physiology and implications. *Nat Rev Endocrinol*. 2018; 14(4):199–215. <https://doi.org/10.1038/nrendo.2017.180> PMID: 29393299
4. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. *Menopause*. 2020; 27(9):976–92. <https://doi.org/10.1097/GME.0000000000001609> PMID: 32852449
5. The 2017 hormone therapy position statement of the North American Menopause Society. *Menopause*. 2017; 24(7):728–53. <https://doi.org/10.1097/GME.0000000000000921> PMID: 28650869
6. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015; 100(11):3975–4011. <https://doi.org/10.1210/jc.2015-2236> PMID: 26444994
7. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet*. 2015; 385(9980):1835–42. [https://doi.org/10.1016/S0140-6736\(14\)61687-1](https://doi.org/10.1016/S0140-6736(14)61687-1) PMID: 25684585
8. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. *Lancet*. 2019; 394(10204):1159–68. [https://doi.org/10.1016/S0140-6736\(19\)31709-X](https://doi.org/10.1016/S0140-6736(19)31709-X) PMID: 31474332
9. Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. *Climacteric*. 2016; 19(2):109–50. <https://doi.org/10.3109/13697137.2015.1129166> PMID: 26872610
10. Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. *JAMA*. 2017; 318(22):2224–33. <https://doi.org/10.1001/jama.2017.18261> PMID: 29234814
11. de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. *Maturitas*. 2016; 91:153–5. <https://doi.org/10.1016/j.maturitas.2016.06.001> PMID: 27389038
12. Sathish M, Eswar R. Systematic reviews and meta-analysis in spine surgery—how good are they in methodological quality? A systematic review. *Global Spine J*. 2021; 11(3):378–99. <https://doi.org/10.1177/2192568220906810> PMID: 32875866
13. Salim A, Mullassery D, Losty PD. Quality of systematic reviews and meta-analyses published in pediatric surgery. *J Pediatr Surg*. 2017; 52(11):1732–5. <https://doi.org/10.1016/j.jpedsurg.2017.07.022> PMID: 28830620
14. Ioannidis JP. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. *Milbank Q*. 2016; 94(3):485–514. <https://doi.org/10.1111/1468-0009.12210> PMID: 27620683

15. Rudmik LR, Walen SG, Dixon E, Dort J. Evaluation of meta-analyses in the otolaryngological literature. *Otolaryngol Head Neck Surg.* 2008; 139(2):187–94. <https://doi.org/10.1016/j.otohns.2008.03.020> PMID: 18656713
16. Delaney A, Bagshaw SM, Ferland A, Manns B, Laupland KB, Doig CJ. A systematic evaluation of the quality of meta-analyses in the critical care literature. *Crit Care.* 2005; 9(5):R575–82. <https://doi.org/10.1186/cc3803> PMID: 16277721
17. Jadad AR, Moher M, Browman GP, Booker L, Sigouin C, Fuentes M, et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. *BMJ.* 2000; 320(7234):537–40. <https://doi.org/10.1136/bmj.320.7234.537> PMID: 10688558
18. Dijkman BG, Abouali JA, Kooistra BW, Conter HJ, Poolman RW, Kulkarni AV, et al. Twenty years of meta-analyses in orthopaedic surgery: has quality kept up with quantity? *J Bone Joint Surg Am.* 2010; 92(1):48–57. <https://doi.org/10.2106/JBJS.I.00251> PMID: 20048095
19. VanderWeele TJ, Mathur MB, Chen Y. Outcome-wide longitudinal designs for causal inference: a new template for empirical studies. *Stat Sci.* 2020; 35(3):437–66.
20. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. *CMAJ.* 2009; 181(8):488–93. <https://doi.org/10.1503/cmaj.081086> PMID: 19654195
21. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. *Int J Evid Based Healthc.* 2015; 13(3):132–40. <https://doi.org/10.1097/XEB.000000000000055> PMID: 26360830
22. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. *Evid Based Ment Health.* 2018; 21(3):95–100. <https://doi.org/10.1136/ebmental-2018-300014> PMID: 30006442
23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *PLoS Med.* 2021; 18(3):e1003583. <https://doi.org/10.1371/journal.pmed.1003583> PMID: 33780438
24. World Health Organization. International classification of diseases, 11th revision. Geneva: World Health Organization; 2020 [cited 2020 Mar 16]. Available from: <https://icd.who.int/browse11/l-m/en>.
25. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. *Eur Heart J.* 2008; 29(16):2031–41. <https://doi.org/10.1093/eurheartj/ehn299> PMID: 18599555
26. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. *Diabetes Obes Metab.* 2006; 8(5):538–54. <https://doi.org/10.1111/j.1463-1326.2005.00545.x> PMID: 16918589
27. Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. *Eur J Cancer.* 2011; 47(17):2607–17. <https://doi.org/10.1016/j.ejca.2011.04.023> PMID: 21620689
28. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. *Asia Pac J Public Health.* 2013; 25(5):368–87. <https://doi.org/10.1177/1010539513488795> PMID: 23709491
29. Mathes T, Klafßen P, Pieper D. Frequency of data extraction errors and methods to increase data extraction quality: a methodological review. *BMC Med Res Methodol.* 2017; 17(1):152. <https://doi.org/10.1186/s12874-017-0431-4> PMID: 29179685
30. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev.* 2017; 1(1):CD004143.
31. Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. *JAMA.* 2020; 324(4):369–80. <https://doi.org/10.1001/jama.2020.9482> PMID: 32721007
32. Chlebowski RT, Wakelee H, Pettinger M, Rohan T, Liu J, Simon M, et al. Estrogen plus progestin and lung cancer: follow-up of the Women's Health Initiative randomized trial. *Clin Lung Cancer.* 2016; 17(1):10–7. <https://doi.org/10.1016/j.clc.2015.09.004> PMID: 26577506
33. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. *JAMA.* 2017; 318(10):927–38. <https://doi.org/10.1001/jama.2017.11217> PMID: 28898378
34. Manson JE, Chlebowski DRT, Stefanick ML, Aragaki MAK, Rossouw JE, Prentice RL, et al. The Women's Health Initiative hormone therapy trials: update and overview of health outcomes during the

- intervention and post-stopping phases. *JAMA*. 2013; 310(13):1353–68. <https://doi.org/10.1001/jama.2013.278040> PMID: 24084921
35. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*. 2017; 358:j4008. <https://doi.org/10.1136/bmj.j4008> PMID: 28935701
 36. Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with dependent effect size estimates. *Res Synth Methods*. 2010; 1(1):39–65. <https://doi.org/10.1002/jrsm.5> PMID: 26056092
 37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002; 21(11):1539–58. <https://doi.org/10.1002/sim.1186> PMID: 12111919
 38. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I^2 in assessing heterogeneity may mislead. *BMC Med Res Methodol*. 2008; 8:79. <https://doi.org/10.1186/1471-2288-8-79> PMID: 19036172
 39. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A Stat Soc*. 2009; 172(1):137–59. <https://doi.org/10.1111/j.1467-985X.2008.00552.x> PMID: 19381330
 40. Wang CC, Lee WC. A simple method to estimate prediction intervals and predictive distributions: summarizing meta-analyses beyond means and confidence intervals. *Res Synth Methods*. 2019; 10(2):255–66. <https://doi.org/10.1002/jrsm.1345> PMID: 30835918
 41. Mathur MB, VanderWeele TJ. New metrics for meta-analyses of heterogeneous effects. *Stat Med*. 2019; 38(8):1336–42. <https://doi.org/10.1002/sim.8057> PMID: 30513552
 42. Mathur MB, VanderWeele TJ. Robust metrics and sensitivity analyses for meta-analyses of heterogeneous effects. *Epidemiology*. 2020; 31(3):356–8. <https://doi.org/10.1097/EDE.0000000000001180> PMID: 32141922
 43. Borenstein M. Research note: in a meta-analysis, the I^2 index does not tell us how much the effect size varies across studies. *J Physiother*. 2020; 66(2):135–9. <https://doi.org/10.1016/j.jphys.2020.02.011> PMID: 32307309
 44. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. *J Clin Epidemiol*. 2000; 53(11):1119–29. [https://doi.org/10.1016/S0895-4356\(00\)00242-0](https://doi.org/10.1016/S0895-4356(00)00242-0) PMID: 11106885
 45. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997; 315(7109):629–34. <https://doi.org/10.1136/bmj.315.7109.629> PMID: 9310563
 46. Vevea JL, Hedges LV. A general linear model for estimating effect size in the presence of publication bias. *Psychometrika*. 1995; 60(3):419–35.
 47. Mathur MB, VanderWeele TJ. Sensitivity analysis for publication bias in meta-analyses. *J R Stat Soc Ser C Appl Stat*. 2020; 69(5):1091–119. <https://doi.org/10.1111/rssc.12440> PMID: 33132447
 48. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med*. 2017; 167(4):268–74. <https://doi.org/10.7326/M16-2607> PMID: 28693043
 49. Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Website and R package for computing E-values. *Epidemiology*. 2018; 29(5):e45–7. <https://doi.org/10.1097/EDE.0000000000000864> PMID: 29912013
 50. Mathur MB, VanderWeele TJ. Sensitivity analysis for unmeasured confounding in meta-analyses. *J Am Stat Assoc*. 2020; 115(529):163–72. <https://doi.org/10.1080/01621459.2018.1529598> PMID: 32981992
 51. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? *Stat Med*. 1984; 3(4):409–22. <https://doi.org/10.1002/sim.4780030421> PMID: 6528136
 52. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. *JAMA*. 1991; 266(1):93–8. PMID: 2046134
 53. Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. *Psychol Bull*. 1995; 117(1):167–78. <https://doi.org/10.1037/0033-2909.117.1.167> PMID: 7870860
 54. VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. *Biometrics*. 2020; 76(3):746–52. <https://doi.org/10.1111/biom.13197> PMID: 31808145
 55. Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. *J Educ Behav Stat*. 1981; 6(2):107–28.
 56. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020 [cited 2020 Mar 16]. Available from: <https://www.R-project.org/>.
 57. Abdi F, Mobedi H, Mosaffa N, Dolatian M, Ramezani Tehrani F. Effects of hormone replacement therapy on immunological factors in the postmenopausal period. *Climacteric*. 2016; 19(3):234–9. <https://doi.org/10.3109/13697137.2016.1164136> PMID: 27086591

58. Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinouadaki I, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis. *Maturitas*. 2017; 99:27–36. <https://doi.org/10.1016/j.maturitas.2017.02.009> PMID: 28364865
59. Benkhadra K, Mohammed K, Al Nofal A, Carranza Leon BG, Alahdab F, Faubion S, et al. Menopausal hormone therapy and mortality: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2015; 100(11):4021–8. <https://doi.org/10.1210/jc.2015-2238> PMID: 26544652
60. Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev*. 2015; 2015(3):CD002229. <https://doi.org/10.1002/14651858.CD002229.pub4> PMID: 25754617
61. Casanova G, Bossardi Ramos R, Ziegelmann P, Spritzer PM. Effects of low-dose versus placebo or conventional-dose postmenopausal hormone therapy on variables related to cardiovascular risk: a systematic review and meta-analyses of randomized clinical trials. *J Clin Endocrinol Metab*. 2015; 100(3):1028–37. <https://doi.org/10.1210/jc.2014-3301> PMID: 25514104
62. Cintron D, Lipford M, Larrea-Mantilla L, Spencer-Bonilla G, Lloyd R, Gionfriddo MR, et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. *Endocrine*. 2017; 55(3):702–11. <https://doi.org/10.1007/s12020-016-1072-9> PMID: 27515805
63. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. *Cochrane Database Syst Rev*. 2012; 10(10):CD001405. <https://doi.org/10.1002/14651858.CD001405.pub3> PMID: 23076892
64. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. *Cochrane Database Syst Rev*. 2012; 2012(8):CD000402. <https://doi.org/10.1002/14651858.CD000402.pub4> PMID: 22895916
65. Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy and skeletal muscle strength: a meta-analysis. *J Gerontol A Biol Sci Med Sci*. 2009; 64(10):1071–81. <https://doi.org/10.1093/gerona/glp082> PMID: 19561145
66. Hogervorst E, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. *Cochrane Database Syst Rev*. 2009; 2009(1):CD003799. <https://doi.org/10.1002/14651858.CD003799.pub2> PMID: 19160224
67. Kongnyuy EJ, Norman RJ, Flight IHK, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. *Cochrane Database Syst Rev*. 1999; 1999(3):CD001018.
68. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev*. 2016; 2016(8):CD001500. <https://doi.org/10.1002/14651858.CD001500.pub3> PMID: 27577677
69. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. *Cochrane Database Syst Rev*. 2008; 2008(1):CD003122. <https://doi.org/10.1002/14651858.CD003122.pub2> PMID: 18254016
70. Lethaby AE, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. The association of oestrogen, oestrogen-progestogen and placebo with endometrial hyperplasia and irregular bleeding in the menopause. *Cochrane Database Syst Rev*. 1999; 1999(2):CD000402.
71. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. *Cochrane Database Syst Rev*. 2004; 2004(4):CD002978. <https://doi.org/10.1002/14651858.CD002978.pub2> PMID: 15495039
72. Nastri CO, Lara LA, Ferriani RA, Rosa ESAC, Figueiredo JB, Martins WP. Hormone therapy for sexual function in perimenopausal and postmenopausal women. *Cochrane Database Syst Rev*. 2013; 2013(6):CD009672. <https://doi.org/10.1002/14651858.CD009672.pub2> PMID: 23737033
73. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev*. 2008; 2008(2):CD005131.
74. Ramesh S, Mann MC, Holroyd-Leduc JM, Wilton SB, James MT, Seely EW, et al. Hormone therapy and clinical and surrogate cardiovascular endpoints in women with chronic kidney disease: a systematic review and meta-analysis. *Menopause*. 2016; 23(9):1028–37. <https://doi.org/10.1097/GME.0000000000000657> PMID: 27433866
75. Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Hormone replacement for osteoporosis in women with primary biliary cirrhosis. *Cochrane Database Syst Rev*. 2011; 2011(12):CD009146. <https://doi.org/10.1002/14651858.CD009146.pub2> PMID: 22161447
76. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. *J Gen Intern Med*. 2004; 19(7):791–804. <https://doi.org/10.1111/j.1525-1497.2004.30281.x> PMID: 15209595

77. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. *BMC Musculoskelet Disord*. 2001; 2(7). <https://doi.org/10.1186/1471-2474-2-7> PMID: 11716794
78. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. *JAMA*. 2001; 285(22):2891–7. <https://doi.org/10.1001/jama.285.22.2891> PMID: 11401611
79. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocr Rev*. 2002; 23(4):529–39. <https://doi.org/10.1210/er.2001-5002> PMID: 12202468
80. Whedon JM, KizhakkeVeetil A, Rugo NA, Kieffer KA. Bioidentical estrogen for menopausal depressive symptoms: a systematic review and meta-analysis. *J Womens Health*. 2017; 26(1):18–28. <https://doi.org/10.1089/jwh.2015.5628> PMID: 27603786
81. Yang D, Li J, Yuan Z, Liu X. Effect of hormone replacement therapy on cardiovascular outcomes: a meta-analysis of randomized controlled trials. *PLoS ONE*. 2013; 8(5):e62329. <https://doi.org/10.1371/journal.pone.0062329> PMID: 23667467
82. Zhu L, Jiang X, Sun Y, Shu W. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. *Menopause*. 2016; 23(4):461–70. <https://doi.org/10.1097/GME.0000000000000519> PMID: 26529613
83. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2012; 21(1):20–38. <https://doi.org/10.1158/1055-9965.EPI-11-0834> PMID: 22028402
84. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. *BMJ*. 2008; 336(7655):1227–31. <https://doi.org/10.1136/bmj.39555.441944.BE> PMID: 18495631
85. Cao Y, Wang Z, Gu J, Hu F, Qi Y, Yin Q, et al. Reproductive factors but not hormonal factors associated with thyroid cancer risk: a systematic review and meta-analysis. *Biomed Res Int*. 2015; 2015:103515. <https://doi.org/10.1155/2015/103515> PMID: 26339585
86. de Klerk BM, Schiphof D, Groeneveld FP, Koes BW, van Osch GJ, van Meurs JB, et al. Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review. *Rheumatology*. 2009; 48(2):104–12. <https://doi.org/10.1093/rheumatology/ken390> PMID: 19000994
87. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol*. 1995; 85(2):304–13. [https://doi.org/10.1016/0029-7844\(94\)00383-O](https://doi.org/10.1016/0029-7844(94)00383-O) PMID: 7824251
88. Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. *Int J Cancer*. 2012; 130(10):2387–96. <https://doi.org/10.1002/ijc.26236> PMID: 21671473
89. Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. *Hum Reprod Update*. 2007; 13(5):453–63. <https://doi.org/10.1093/humupd/dmm012> PMID: 17573406
90. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. *Ann Intern Med*. 2002; 137(4):273–84. <https://doi.org/10.7326/0003-4819-137-4-200208200-00012> PMID: 12186518
91. Lai K, Cui J, Ni S, Zhang Y, He J, Yao K. The effects of postmenopausal hormone use on cataract: a meta-analysis. *PLoS ONE*. 2013; 8(10):e78647. <https://doi.org/10.1371/journal.pone.0078647> PMID: 24205286
92. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. *JAMA*. 2001; 285(11):1489–99. <https://doi.org/10.1001/jama.285.11.1489> PMID: 11255426
93. Li W, Lin X, Wang R, Wang F, Xie S, Tse LA. Hormone therapy and lung cancer mortality in women: systematic review and meta-analysis. *Steroids*. 2017; 118:47–54. <https://doi.org/10.1016/j.steroids.2016.12.005> PMID: 27964943
94. McCarthy CE, Field JK, Marcus MW. Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (review). *Oncol Rep*. 2017; 38(4):1915–22. <https://doi.org/10.3892/or.2017.5867> PMID: 28765919
95. McCleary N, Nwaru BI, Nurmatov UB, Critchley H, Sheikh A. Endogenous and exogenous sex steroid hormones in asthma and allergy in females: a systematic review and meta-analysis. *J Allergy Clin Immunol*. 2018; 141(4):1510–3.e8. <https://doi.org/10.1016/j.jaci.2017.11.034> PMID: 29305316

96. Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z. Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. *PLoS ONE*. 2013; 8(12):e83261. <https://doi.org/10.1371/journal.pone.0083261> PMID: 24386167
97. Qi ZY, Shao C, Zhang X, Hui GZ, Wang Z. Exogenous and endogenous hormones in relation to glioma in women: a meta-analysis of 11 case-control studies. *PLoS ONE*. 2013; 8(7):e68695. <https://doi.org/10.1371/journal.pone.0068695> PMID: 23874728
98. Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg AM. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. *PLoS ONE*. 2014; 9(8):e104303. <https://doi.org/10.1371/journal.pone.0104303> PMID: 25137236
99. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. *Am J Med*. 2009; 122(11):1016–22.e1. <https://doi.org/10.1016/j.amjmed.2009.05.021> PMID: 19854329
100. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. *Eur J Cancer*. 2014; 50(9):1628–37. <https://doi.org/10.1016/j.ejca.2014.03.006> PMID: 24685478
101. Tang B, Lv J, Li Y, Yuan S, Wang Z, He S. Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. *Medicine*. 2015; 94(7):e177. <https://doi.org/10.1097/MD.000000000000177> PMID: 25700305
102. Wang P, Li J, Qiu S, Wen H, Du J. Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studies. *Neuropsychiatr Dis Treat*. 2015; 11:59–66. <https://doi.org/10.2147/NDT.S69918> PMID: 25657580
103. Wang S, Wang Y, Xu J, Chen Y. Is the oral contraceptive or hormone replacement therapy a risk factor for cholelithiasis: a systematic review and meta-analysis. *Medicine*. 2017; 96(14):e6556. <https://doi.org/10.1097/MD.0000000000006556> PMID: 28383429
104. Yao Y, Gu X, Zhu J, Yuan D, Song Y. Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. *PLoS ONE*. 2013; 8(8):e71236. <https://doi.org/10.1371/journal.pone.0071236> PMID: 23967172
105. Yu X, Zhou S, Wang J, Zhang Q, Hou J, Zhu L, et al. Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies. *Breast Cancer*. 2017; 24(5):643–57. <https://doi.org/10.1007/s12282-017-0789-5> PMID: 28601917
106. Zhong GC, Liu Y, Chen N, Hao FB, Wang K, Cheng JH, et al. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies. *Hum Reprod Update*. 2016; 23(1):126–38. <https://doi.org/10.1093/humupd/dmw037> PMID: 27655589
107. Zhu Y, Yue D, Yuan B, Zhu L, Lu M. Reproductive factors are associated with oesophageal cancer risk: results from a meta-analysis of observational studies. *Eur J Cancer Prev*. 2017; 26(1):1–9. <https://doi.org/10.1097/CEJ.000000000000234> PMID: 26886236
108. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. *Breast Cancer Res*. 2005; 7(4):R535–40. <https://doi.org/10.1186/bcr1035> PMID: 15987460
109. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. *Gynecol Oncol*. 2015; 139(2):355–62. <https://doi.org/10.1016/j.ygyno.2015.07.109> PMID: 26232517
110. O'Brien J, Jackson JW, Grodstein F, Blacker D, Weuve J. Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease. *Epidemiol Rev*. 2014; 36(1):83–103.
111. Xu Y, Lin J, Wang S, Xiong J, Zhu Q. Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus. *Kaohsiung J Med Sci*. 2014; 30(7):350–61. <https://doi.org/10.1016/j.kjms.2014.03.002> PMID: 24924841
112. Serghiou S, Goodman SN. Random-effects meta-analysis: summarizing evidence with caveats. *JAMA*. 2019; 321(3):301–2. <https://doi.org/10.1001/jama.2018.19684> PMID: 30566189
113. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*. 2011; 342:d549. <https://doi.org/10.1136/bmj.d549> PMID: 21310794
114. Wang T, Bradshaw PT, Moorman PG, Nyante SJ, Nichols HB, Shantakumar S, et al. Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project. *Int J Cancer*. 2020; 147(12):3404–15. <https://doi.org/10.1002/ijc.33174> PMID: 32588422

115. Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, et al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecol Oncol*. 2020; 158(3):702–9. <https://doi.org/10.1016/j.ygyno.2020.06.481> PMID: 32641237
116. Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer mortality. *Lancet*. 2019; 394(10204):1139. [https://doi.org/10.1016/S0140-6736\(19\)32033-1](https://doi.org/10.1016/S0140-6736(19)32033-1) PMID: 31474331
117. Ellis L, Woods LM, Estève J, Eloranta S, Coleman MP, Rachet B. Cancer incidence, survival and mortality: explaining the concepts. *Int J Cancer*. 2014; 135(8):1774–82. <https://doi.org/10.1002/ijc.28990> PMID: 24945976
118. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. *Lancet*. 2004; 363(9407):453–5. [https://doi.org/10.1016/S0140-6736\(04\)15493-7](https://doi.org/10.1016/S0140-6736(04)15493-7) PMID: 14962527
119. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. *J Natl Cancer Inst*. 2008; 100(7):475–82. <https://doi.org/10.1093/jnci/djn058> PMID: 18364505
120. Dyer O. Another HRT trial is stopped early. *BMJ*. 2004; 328(7435):305. <https://doi.org/10.1136/bmj.328.7435.305> PMID: 14764470
121. Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. *Eur J Cancer*. 2013; 49(1):52–9. <https://doi.org/10.1016/j.ejca.2012.07.003> PMID: 22892060
122. Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health. *Menopause*. 2018; 25(6):596–608. <https://doi.org/10.1097/GME.0000000000001121> PMID: 29762200
123. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. *Climacteric*. 2012; 15(3):217–28. <https://doi.org/10.3109/13697137.2012.656401> PMID: 22612607
124. Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. *Menopause*. 2013; 20(3):342–53. <https://doi.org/10.1097/GME.0b013e3182843aad> PMID: 23435033
125. Lobo RA. Hormone-replacement therapy: current thinking. *Nat Rev Endocrinol*. 2017; 13(4):220–31. <https://doi.org/10.1038/nrendo.2016.164> PMID: 27716751
126. Manson JE, Bassuk SS, Kaunitz AM, Pinkerton JV. The Women's Health Initiative trials of menopausal hormone therapy: lessons learned. *Menopause*. 2020; 27(8):918–28. <https://doi.org/10.1097/GME.0000000000001553> PMID: 32345788
127. Langer RD, Simon JA, Pines A, Lobo RA, Hodis HN, Pickar JH, et al. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. *Climacteric*. 2017; 20(5):402–13. <https://doi.org/10.1080/13697137.2017.1362156> PMID: 28805475
128. Keaney JF Jr, Solomon CG. Postmenopausal hormone therapy and atherosclerosis—time is of the essence. *N Engl J Med*. 2016; 374(13):1279–80. <https://doi.org/10.1056/NEJMe1602846> PMID: 27028919
129. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. *J Gen Intern Med*. 2006; 21(4):363–6. <https://doi.org/10.1111/j.1525-1497.2006.00389.x> PMID: 16686814
130. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. *Ann Intern Med*. 1992; 116(1):78–84. <https://doi.org/10.7326/0003-4819-116-1-78> PMID: 1530753
131. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. *BMJ*. 2010; 340:c117. <https://doi.org/10.1136/bmj.c117> PMID: 20354011
132. Gartlehner G, Patel SV, Feltner C, Weber RP, Long R, Mullican K, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2017; 318(22):2234–49. <https://doi.org/10.1001/jama.2017.16952> PMID: 29234813
133. Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. *Clin Epidemiol Glob Health*. 2019; 7(2):192–8.
134. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. *N Engl J Med*. 2016; 374(13):1221–31. <https://doi.org/10.1056/NEJMoa1505241> PMID: 27028912

135. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. *Ann Intern Med*. 2014; 161(4):249–60. <https://doi.org/10.7326/M14-0353> PMID: 25069991
136. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med*. 2006; 354(12):1264–72. <https://doi.org/10.1056/NEJMoa054013> PMID: 16554528
137. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J*. 2015; 36(9):539–50. <https://doi.org/10.1093/eurheartj/ehv571> PMID: 24474739
138. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet*. 2010; 375(9726):1634–9. [https://doi.org/10.1016/S0140-6736\(10\)60545-4](https://doi.org/10.1016/S0140-6736(10)60545-4) PMID: 20452521
139. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. *JAMA*. 2009; 301(22):2331–9. <https://doi.org/10.1001/jama.2009.801> PMID: 19509380
140. Song C, Burgess S, Eicher JD, O'Donnell CJ, Johnson AD. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. *J Am Heart Assoc*. 2017; 6(6):e004918. <https://doi.org/10.1161/JAHA.116.004918> PMID: 28550093
141. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. *JAMA*. 2005; 293(8):935–48. <https://doi.org/10.1001/jama.293.8.935> PMID: 15728164
142. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods*. 2010; 1(2):97–111. <https://doi.org/10.1002/jrsm.12> PMID: 26061376